Importantly, non-Bcl2-engineered Suv39h1− LC presented—like control lymphomas, but different from apoptosis-compromised p53null lymphomas—with exquisite apoptotic drug sensitivity, thus highlighting their selective senescence defect while apoptosis remains intact (Supplementary Fig. 3c). The gene discussed is BCL2; the disease is lymphoma.